Background and objectives
=========================

PreImplantation factor (PIF) secreted by viable embryos exerts essential regulatory role on global systemic immune response. Synthetic PIF (PIF) translates endogenous effects to immune disorder models. Metastatic melanoma displays tumor-immunological behaviour. Static magnetic field (SMF) affects inflammatory reactions. There is increased interest toward SMF's potential anti-tumor effects. Herein examined a novel anti-melanoma strategy using combined physical and immune-based therapy.

Methods
=======

Daily whole-body SMF exposure, combined with subcutaneous PIF administration was examined in engrafted HT199 melanoma cells' progression, transplanted into NSG mice. PIF effect on unique tumor-associated antigen expression relevant for tumor proliferation/ invasion was examined in vitro using specific antibodies. Direct PIF anti-proliferative effects on several cancer cell lines were tested using MTT.

Results
=======

PIF potentiates SMF beneficial effect by reducing tumor volume vs. control (Mmax=96%) on day 34. Metastatic spleen mass is reduced by SMF alone (M=59%) or combined with PIF (M=62%). Daily SMF exposure alone inhibits tumor outgrowth (Mmax=60%, F5.32 (P\<0.002)=21.16) while in combination with PIF, effect is considerably potentiated (M=80%), F5.32(P\<0.0004)=34.84). PIF did not impair tumor antigen expression nor reduced significantly cultured tumor cell lines' proliferation.

Conclusions
===========

Collectively, results indicate that PIF's potentiating anti-tumoral effect is mainly immune-regulatory, synergizing with SMF's pro-tumor necrosis properties. The preserved tumor-associated antigen expression is important for the maintained antitumor immune activity. Overall, combined physico / immune regulatory treatment represents a useful, promising novel avenue for anti-cancer strategy.
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